Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M360Revenue $M6.1Net Margin (%)--Altman Z-Score23.5
Enterprise Value $M285EPS $-1.1Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score-4.6Pre-tax Margin (%)--Higher ROA y-yY
Price/Book3.610-y EBITDA Growth Rate %--Quick Ratio9.8Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio9.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-37.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-40.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M43.7ROIC % (ttm)-190.6Gross Margin Increase y-yN

Gurus Latest Trades with CCXI

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

CCXI is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CCXI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BVF PARTNERS L P/IL10% Owner 2015-06-10Sell955,700$9-8.44 view
Parker Geoffrey M.Director 2015-05-27Sell13,513$7.519.72 view
Tyree James LDirector 2015-05-22Sell12,703$7.4510.6 view
KLEIN IRADirector 2015-05-22Sell10,811$7.4410.75 view
Schall Thomas J.President and CEO 2015-04-01Sell24,267$7.59.87 view
Schall Thomas J.President and CEO 2015-03-25Sell900$7.578.85 view
Schall Thomas J.President and CEO 2015-03-24Sell50,371$7.845.1 view
Schall Thomas J.President and CEO 2015-03-19Sell18,146$8.34-1.2 view
Schall Thomas J.President and CEO 2015-03-17Sell31,316$8.55-3.63 view
Cappel Markus J.Chief Bus. Officer & Treasurer 2015-03-09Sell34,125$7.815.51 view

Quarterly/Annual Reports about CCXI:

News about CCXI:

Articles On GuruFocus.com
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
New ipo recommended Sep 16 2012 

More From Other Websites
CHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Jul 30 2015
ChemoCentryx Announces Changes to its Board of Directors Jul 30 2015
ChemoCentryx Announces Changes to its Board of Directors Jul 30 2015
ChemoCentryx to Hold Second Quarter 2015 Financial Results Conference Call on Thursday, August 6,... Jul 29 2015
ChemoCentryx to Hold Second Quarter 2015 Financial Results Conference Call on Thursday, August 6,... Jul 29 2015
Positive Results From ChemoCentryx Phase II Diabetic Nephropathy Trial With Chemokine Receptor CCR2... May 29 2015
Positive Clinical Data From ChemoCentryx Phase II Trial in Diabetic Nephropathy to be Presented at... May 26 2015
Positive Clinical Data From ChemoCentryx Phase II Trial in Diabetic Nephropathy to be Presented at... May 26 2015
CHEMOCENTRYX, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 22 2015
ChemoCentryx upgraded by JP Morgan May 18 2015
CHEMOCENTRYX, INC. Financials May 15 2015
ChemoCentryx to Present at Two Upcoming Investor Conferences May 12 2015
ChemoCentryx to Present at Two Upcoming Investor Conferences May 12 2015
CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report May 08 2015
ChemoCentryx Inc Earnings Call scheduled for 5:00 pm ET today May 06 2015
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 06 2015
ChemoCentryx Reports First Quarter 2015 Financial Results and Provides Corporate Update May 06 2015
Q1 2015 ChemoCentryx Inc Earnings Release - After Market Close May 06 2015
ChemoCentryx to Hold First Quarter 2015 Financial Results Conference Call on Wednesday, May 6, 2015 Apr 22 2015
ChemoCentryx Initiates Clinical Trial of CCX872, Its Next-Generation, Orally Administered CCR2... Apr 20 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK